Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Epacadostat vs Standard of Care in First-Line Advanced Renal Cell Carcinoma
NCT03260894Phase 3Completed
- Sponsor
- Incyte
- Start
- Dec 2017
- Primary completion
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of pembrolizumab, epacadostat in renal cell carcinoma (RCC), sponsored by Incyte. Started Dec 2017; status: completed.
02
Drugs
pembrolizumabepacadostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03260894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260894.